SG11202005733QA - Diazaindole compounds - Google Patents
Diazaindole compoundsInfo
- Publication number
- SG11202005733QA SG11202005733QA SG11202005733QA SG11202005733QA SG11202005733QA SG 11202005733Q A SG11202005733Q A SG 11202005733QA SG 11202005733Q A SG11202005733Q A SG 11202005733QA SG 11202005733Q A SG11202005733Q A SG 11202005733QA SG 11202005733Q A SG11202005733Q A SG 11202005733QA
- Authority
- SG
- Singapore
- Prior art keywords
- diazaindole
- compounds
- diazaindole compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762607941P | 2017-12-20 | 2017-12-20 | |
PCT/US2018/066108 WO2019126083A1 (en) | 2017-12-20 | 2018-12-18 | Diazaindole compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202005733QA true SG11202005733QA (en) | 2020-07-29 |
Family
ID=65003573
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202005733QA SG11202005733QA (en) | 2017-12-20 | 2018-12-18 | Diazaindole compounds |
Country Status (14)
Country | Link |
---|---|
US (1) | US11299501B2 (en) |
EP (1) | EP3728264B1 (en) |
JP (1) | JP7382938B2 (en) |
KR (1) | KR20200100760A (en) |
CN (1) | CN111511744B (en) |
AU (1) | AU2018390544A1 (en) |
BR (1) | BR112020012002A2 (en) |
CA (1) | CA3085937A1 (en) |
EA (1) | EA202091530A1 (en) |
ES (1) | ES2904773T3 (en) |
IL (1) | IL275505A (en) |
MX (1) | MX2020006014A (en) |
SG (1) | SG11202005733QA (en) |
WO (1) | WO2019126083A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
ES2904676T3 (en) * | 2017-12-20 | 2022-04-05 | Bristol Myers Squibb Co | Amino indole compounds useful as TLR inhibitors |
CA3085942A1 (en) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Aryl and heteroaryl substituted indole compounds |
JP7328977B2 (en) | 2018-02-12 | 2023-08-17 | エフ. ホフマン-ラ ロシュ アーゲー | Novel sulfone compounds and derivatives for the treatment and prevention of viral infections |
CN112313228A (en) | 2018-06-12 | 2021-02-02 | 豪夫迈·罗氏有限公司 | Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune diseases |
US11952363B2 (en) | 2018-07-23 | 2024-04-09 | Hoffmann-La Roche Inc. | Piperazine compounds for the treatment of autoimmune disease |
WO2020048583A1 (en) | 2018-09-04 | 2020-03-12 | F. Hoffmann-La Roche Ag | Benzothiazole compounds for the treatment of autoimmune diseases |
EP3847170B1 (en) | 2018-09-06 | 2022-06-22 | F. Hoffmann-La Roche AG | Novel cyclic amidine compounds for the treatment of autoimmune disease |
CN116848119A (en) * | 2021-02-08 | 2023-10-03 | 杭州中美华东制药有限公司 | Pyrrolopyridazine compound, and preparation method and application thereof |
CA3214808A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Thienopyrrole compounds |
WO2023159154A1 (en) * | 2022-02-18 | 2023-08-24 | Bristol-Myers Squibb Company | Substituted imidazopyridinyl compounds useful as inhibitors of tlr9 |
CN114591339B (en) * | 2022-05-10 | 2022-08-02 | 上海维申医药有限公司 | Toll-like receptor inhibitor and preparation and application thereof |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6187777B1 (en) * | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
CZ20012006A3 (en) | 1998-12-18 | 2002-03-13 | Axys Pharmaceuticals, Inc. | Compound and pharmaceutical preparation |
TR200201051T2 (en) | 1999-10-19 | 2002-09-23 | Merck & Co., Inc. | Tyrosine kinase inhibitors. |
KR101108722B1 (en) | 2002-01-07 | 2012-02-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Deazapurines and uses thereof |
CA2528774A1 (en) | 2003-06-20 | 2005-01-27 | Coley Pharmaceutical Gmbh | Small molecule toll-like receptor (tlr) antagonists |
US20060235037A1 (en) * | 2005-04-15 | 2006-10-19 | Purandare Ashok V | Heterocyclic inhibitors of protein arginine methyl transferases |
AU2007234399A1 (en) | 2006-04-04 | 2007-10-11 | Myriad Genetics, Inc. | Compounds for diseases and disorders |
DE102006033109A1 (en) | 2006-07-18 | 2008-01-31 | Grünenthal GmbH | Substituted heteroaryl derivatives |
US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
JP2010511018A (en) | 2006-12-01 | 2010-04-08 | ガラパゴス・ナムローゼ・フェンノートシャップ | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases |
WO2008152471A1 (en) | 2007-06-12 | 2008-12-18 | Coley Pharmaceutical Group, Inc. | Quinazoline derivative useful as toll-like receptor antagonist |
WO2009030996A1 (en) | 2007-09-05 | 2009-03-12 | Coley Pharmaceutical Group, Inc. | Triazole compounds as toll-like receptor (tlr) agonists |
WO2009042092A1 (en) | 2007-09-25 | 2009-04-02 | Merck & Co., Inc. | 2-aryl or heteroaryl indole derivatives |
EP2350032B1 (en) | 2008-09-26 | 2016-05-25 | Eisai R&D Management Co., Ltd. | Benzoxazole compounds and methods of use |
US8785489B2 (en) | 2008-10-17 | 2014-07-22 | Boehringer Ingelheim International Gmbh | Heteroaryl substituted indole compounds useful as MMP-13 inhibitors |
TWI462920B (en) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | Novel compound useful for the treatment of degenerative and inflammatory diseases |
CA2768236C (en) | 2009-07-16 | 2018-05-22 | Mallinckrodt Llc | (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
CN102574788A (en) | 2009-09-24 | 2012-07-11 | 弗·哈夫曼-拉罗切有限公司 | Indole derivatives as crac modulators |
AU2010310449A1 (en) | 2009-10-22 | 2012-05-03 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
JP2013166700A (en) * | 2010-06-02 | 2013-08-29 | Dainippon Sumitomo Pharma Co Ltd | Novel 4, 5-fused pyrimidine derivative |
WO2012054862A2 (en) | 2010-10-21 | 2012-04-26 | The Brigham And Women's Hospital, Inc. | Agents, compositions, and methods for treating pruritis and related skin conditions |
MX348935B (en) | 2011-01-12 | 2017-07-03 | Ventirx Pharmaceuticals Inc | Substituted benzoazepines as toll-like receptor modulators. |
MX346387B (en) | 2011-01-12 | 2017-03-02 | Ventirx Pharmaceuticals Inc | Substituted benzoazepines as toll-like receptor modulators. |
JP6093759B2 (en) | 2011-06-01 | 2017-03-08 | ジャナス バイオセラピューティクス,インク. | Novel immune system modulators |
WO2012167053A1 (en) | 2011-06-01 | 2012-12-06 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
AU2012267556B9 (en) | 2011-06-09 | 2017-05-11 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of GPR-119 |
IN2014MN00258A (en) | 2011-07-15 | 2015-09-25 | Janssen Pharmaceuticals Inc | |
JP2013075834A (en) * | 2011-09-29 | 2013-04-25 | Kowa Co | Pyrazolopyrimidine-7-amine derivative exhibiting tlr9-inhibiting activity |
WO2013052550A2 (en) | 2011-10-04 | 2013-04-11 | Janus Biotherapeutics, Inc. | Novel imidazole quinoline-based immune system modulators |
US20130158040A1 (en) | 2011-12-20 | 2013-06-20 | Hoffmann-La Roche Inc. | Diazaindole inhibitors of crac |
ES2644702T3 (en) | 2012-05-18 | 2017-11-30 | Sumitomo Dainippon Pharma Co., Ltd. | Carboxylic acid compounds |
JO3407B1 (en) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | Tetrahydropyrazolopyrimidine Compounds |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
EP2738172A1 (en) | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
AU2014334554B2 (en) | 2013-10-14 | 2018-12-06 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
CA2933466A1 (en) | 2013-12-13 | 2015-06-18 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors |
SG11201701169XA (en) | 2014-08-15 | 2017-03-30 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Pyrrolopyrimidine compounds used as tlr7 agonist |
US20170275287A1 (en) | 2014-08-22 | 2017-09-28 | Janus Biotherapeutics, Inc. | Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof |
US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
US11180474B2 (en) | 2016-07-30 | 2021-11-23 | Bristol-Myers Squibb Company | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors |
EP3510024B1 (en) | 2016-09-09 | 2021-11-17 | Bristol-Myers Squibb Company | Pyridyl substituted indole compounds |
KR20200086709A (en) | 2017-11-14 | 2020-07-17 | 브리스톨-마이어스 스큅 컴퍼니 | Substituted indole compounds |
FI3728252T3 (en) | 2017-12-18 | 2023-10-18 | Bristol Myers Squibb Co | 4-azaindole compounds |
EP3728253B1 (en) | 2017-12-19 | 2024-03-27 | Bristol-Myers Squibb Company | 6-azaindole compounds |
-
2018
- 2018-12-18 CA CA3085937A patent/CA3085937A1/en active Pending
- 2018-12-18 JP JP2020534861A patent/JP7382938B2/en active Active
- 2018-12-18 KR KR1020207020851A patent/KR20200100760A/en not_active Application Discontinuation
- 2018-12-18 MX MX2020006014A patent/MX2020006014A/en unknown
- 2018-12-18 ES ES18830674T patent/ES2904773T3/en active Active
- 2018-12-18 BR BR112020012002-2A patent/BR112020012002A2/en not_active Application Discontinuation
- 2018-12-18 AU AU2018390544A patent/AU2018390544A1/en not_active Abandoned
- 2018-12-18 SG SG11202005733QA patent/SG11202005733QA/en unknown
- 2018-12-18 WO PCT/US2018/066108 patent/WO2019126083A1/en unknown
- 2018-12-18 EA EA202091530A patent/EA202091530A1/en unknown
- 2018-12-18 EP EP18830674.0A patent/EP3728264B1/en active Active
- 2018-12-18 US US16/955,108 patent/US11299501B2/en active Active
- 2018-12-18 CN CN201880082762.7A patent/CN111511744B/en active Active
-
2020
- 2020-06-18 IL IL275505A patent/IL275505A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3728264A1 (en) | 2020-10-28 |
CN111511744A (en) | 2020-08-07 |
CN111511744B (en) | 2023-09-22 |
KR20200100760A (en) | 2020-08-26 |
AU2018390544A1 (en) | 2020-08-06 |
BR112020012002A2 (en) | 2020-11-17 |
EP3728264B1 (en) | 2021-12-01 |
EA202091530A1 (en) | 2020-09-14 |
MX2020006014A (en) | 2020-08-17 |
IL275505A (en) | 2020-08-31 |
CA3085937A1 (en) | 2019-06-27 |
JP7382938B2 (en) | 2023-11-17 |
US20200308195A1 (en) | 2020-10-01 |
WO2019126083A1 (en) | 2019-06-27 |
ES2904773T3 (en) | 2022-04-06 |
JP2021506941A (en) | 2021-02-22 |
US11299501B2 (en) | 2022-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB201708456D0 (en) | Senolytic compounds | |
GB201704327D0 (en) | Compounds | |
GB201700814D0 (en) | Compounds | |
IL275505A (en) | Diazaindole compounds | |
GB201704325D0 (en) | Compounds | |
IL292485B2 (en) | Pyridylpyridone compounds | |
GB201716871D0 (en) | Compounds | |
GB201717051D0 (en) | Compounds | |
GB201707938D0 (en) | Compounds | |
GB201706162D0 (en) | Compounds | |
GB201715786D0 (en) | Compounds | |
GB201707856D0 (en) | Compounds | |
GB201702221D0 (en) | Compounds | |
GB201716369D0 (en) | Compounds | |
GB201707852D0 (en) | Compounds | |
GB201703282D0 (en) | Compounds | |
GB201721326D0 (en) | Compounds | |
GB201721330D0 (en) | Compounds | |
GB201721331D0 (en) | Compounds | |
GB201720495D0 (en) | ß-lactone compounds | |
GB201720064D0 (en) | Compounds | |
GB201719261D0 (en) | Compounds | |
GB201717718D0 (en) | Compounds | |
GB201717050D0 (en) | Compounds | |
GB201716688D0 (en) | Compounds |